Abstract
Background Obstructive sleep apnea (OSA) is a heterogeneous disease, with obesity a significant risk factor via increased airway collapsibility, reduced lung volumes, and possibly body fat distribution.
Methods Using race/ethnic diverse samples from the Million Veteran Program, FinnGen, TOPMed, All of Us (AoU), Geisinger’s MyCode, MGB Biobank, and the Human Phenotype Project (HPP), we developed, selected, and assessed polygenic scores (PGSs) for OSA, relying on genome-wide association studies both adjusted and unadjusted for BMI: BMIadjOSA- and BMIunadjOSA-PGS. We tested their associations with CVD in AoU.
Results Adjusted odds ratios (ORs) for OSA per 1 standard deviation of the PGSs ranged from 1.38 to 2.75. The associations of BMIadjOSA- and BMIunadjOSA-PGSs with CVD outcomes in AoU shared both common and distinct patterns. For example, BMIunadjOSA-PGS was associated with type 2 diabetes, heart failure, and coronary artery disease, but the associations of BMIadjOSA-PGS with these outcomes were statistically insignificant with estimated OR close to 1. In contrast, both BMIadjOSA- and BMIunadjOSA-PGSs were associated with hypertension and stroke. Sex stratified analyses revealed that BMIadjOSA-PGS association with hypertension was driven by data from OR=1.1, p-value=0.002, OR=1.01 p-value=0.2 in males). OSA PGSs were also associated with dual-energy X-ray absorptiometry (DXA) body fat measures with some sex-specific associations.
Conclusions Distinct components of OSA genetic risk are related to obesity and body fat distribution, and may influence clinical outcomes. These may explain differing OSA risks and associations with cardiometabolic morbidities between sex groups.
Competing Interest Statement
Dr. Redline discloses consulting relationships with Eli Lilly Inc. Additionally, Dr. Redline serves as an unpaid member of the Apnimed Scientific Advisory Board, as an unpaid board member for the Alliance for Sleep Apnoea Partners, and has received loaned equipment for a multi-site study: oxygen concentrators from Philips Respironics and polysomnography equipment from Nox Medical. BP serves on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. SSR and LMR are consultants to the TOPMed Administrative Coordinating Center (through Westat).
Funding Statement
This work is supported by National Heart, Lung, and Blood Institute (NHLBI) grant R01HL161012 and National Aging Institute grant R01AG080598 grant to TS. This research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration, and was supported by award #MVP001 and #BX004821. TS was also supported by Human Genome Research Institute (NHGRI) grant R56HG013163. HMO was supported by National Cancer Institute grant R01CA283469, National Institute of Allergy and Infectious Diseases grant R01AI170850, and by NHGRI grant R01HG012810. This analysis was approved by the Beth Israel Deaconess Medical Center Committee on Clinical Investigations, protocol #2023P000279, and by the Mass General Brigham IRB, protocol #2021P001928. AEJ, GC, and SG were all funded by the National Institutes of Health (NIH), National Heart Lung and Blood Institute (NHLBI) grant P01 HL160471 - 8274.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
MVP received ethical/study protocol approval from the VA Central Institutional Review Board, and written informed consent was obtained for all participants. Study subjects in FinnGen provided informed consent for biobank research in accordance with the Finnish Biobank Act. The full ethics statement is as follows: Study subjects in FinnGen provided informed consent for biobank research, based on the Finnish Biobank Act. Alternatively, separate research cohorts, collected prior the Finnish Biobank Act came into effect (in September 2013) and start of FinnGen (August 2017), were collected based on study-specific consents and later transferred to the Finnish biobanks after approval by Fimea (Finnish Medicines Agency), the National Supervisory Authority for Welfare and Health. Recruitment protocols followed the biobank protocols approved by Fimea. The Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS) statement number for the FinnGen study is Nr HUS/990/2017. The FinnGen study Is approved by Finnish Institute for Health and Welfare (permit numbers: THL/2031/6.02.00/2017, THL/1101/5.05.00/2017, THL/341/6.02.00/2018, THL/2222/6.02.00/2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019 and THL/1524/5.05.00/2020), Digital and population data service agency (permit numbers: VRK43431/2017-3, VRK/6909/2018-3, VRK/4415/2019-3), the Social Insurance Institution (permit numbers: KELA 58/522/2017, KELA 131/522/2018, KELA 70/522/2019, KELA 98/522/2019, KELA 134/522/2019, KELA 138/522/2019, KELA 2/522/2020, KELA 16/522/2020), Findata permit numbers THL/2364/14.02/2020, THL/4055/14.06.00/2020, THL/3433/14.06.00/2020, THL/4432/14.06/2020, THL/5189/14.06/2020, THL/5894/14.06.00/2020, THL/6619/14.06.00/2020, THL/209/14.06.00/2021, THL/688/14.06.00/2021, THL/1284/14.06.00/2021, THL/1965/14.06.00/2021, THL/5546/14.02.00/2020, THL/2658/14.06.00/2021, THL/4235/14.06.00/2021, Statistics Finland (permit numbers: TK-53-1041-17 and TK/143/07.03.00/2020 (earlier TK-53-90-20) TK/1735/07.03.00/2021, TK/3112/07.03.00/2021) and Finnish Registry for Kidney Diseases permission/extract from the meeting minutes on 4th July 2019. The Biobank Access Decisions for FinnGen samples and data utilized in FinnGen Data Freeze 10 include: THL Biobank BB2017_55, BB2017_111, BB2018_19, BB_2018_34, BB_2018_67, BB2018_71, BB2019_7, BB2019_8, BB2019_26, BB2020_1, BB2021_65, Finnish Red Cross Blood Service Biobank 7.12.2017, Helsinki Biobank HUS/359/2017, HUS/248/2020, HUS/430/2021 28, 29, HUS/150/2022 12, 13, 14, 15, 16, 17, 18, 23, 58 and 59, Auria Biobank AB17-5154 and amendment #1 (August 17 2020) and amendments BB_2021-0140, BB_2021- 0156 (August 26 2021, Feb 2 2022), BB_2021-0169, BB_2021-0179, BB_2021-0161, AB20-5926 and amendment #1 (April 23 2020) and it ́s modification (Sep 22 2021), BB_2022-0262, BB_2022-0256, Biobank Borealis of Northern Finland_2017_1013, 2021_5010, 2021_5018, 2021_5015, 2021_5015 Amendment, 2021_5023, 2021_5023 Amendment, 2021_5017, 2022_6001, 2022_6006 Amendment, BB22-0067, 2022_0262, Biobank of Eastern Finland 1186/2018 and amendment 22/2020, 53/2021, 13/2022, 14/2022, 15/2022, 27/2022, 28/2022, 29/2022, 33/2022, 35/2022, 36/2022, 37/2022, 39/2022, 7/2023, Finnish Clinical Biobank Tampere MH0004 and amendments (21.02.2020 & 06.10.2020), 8/2021, 9/2021, 9/2022, 10/2022, 12/2022, 13/2022, 20/2022, 21/2022, 22/2022, 23/2022, 28/2022, 29/2022, 30/2022, 31/2022, 32/2022, 38/2022, 40/2022, 42/2022, 1/2023, Central Finland Biobank 1-2017, BB_2021-0161, BB_2021-0169, BB_2021-0179, BB_2021-0170, BB_2022-0256, and Terveystalo Biobank STB 2018001 and amendment 25th Aug 2020, Finnish Hematological Registry and Clinical Biobank decision 18th June 2021, Arctic biobank P0844: ARC_2021_1001. The All of Us research program was approved by a single IRB, the 'All of Us IRB', which is charged with reviewing the protocol, informed consent, and other participant-facing materials for the All of Us Research Program. The IRB follows the regulations and guidance of the Office for Human Research Protections for all studies, ensuring that the rights and welfare of research participants are overseen and protected uniformly. More information is provided online: https://allofus.nih.gov/about/who-we-are/institutional-review-board-irb-of-all-of-us-research-program. All MGB Biobank subjects have provided their consent to join the MGB Biobank, which includes agreeing to provide a blood sample linked to the electronic medical record. Subjects also agree to be recontacted by the MGB Biobank staff as needed. This manuscript utilized data from 10 different studies within TOPMed. Ethical approval was obtained for each individual study, as follows: ARIC: The ARIC study has been approved by a single Institutional Review Board (sIRB) at Johns Hopkins School of Medicine and Institutional Review Boards (IRB) at all participating institutions: University of North Carolina at Chapel Hill IRB, Johns Hopkins University School of Public Health IRB, University of Minnesota IRB, Wake Forest University Health Sciences IRB, and University of Mississippi Medical Center IRB. Study participants provided written informed consent at all study visits. CARDIA: All CARDIA participants provided informed consent, and the study was approved by the Institutional Review Boards of the University of Alabama at Birmingham and the University of Texas Health Science Center at Houston. CFS: Cleveland Family Study was approved by the Institutional Review Board (IRB) of Case Western Reserve University and Mass General Brigham (formerly Partners HealthCare). Written informed consent was obtained from all participants. CHS: CHS was approved by institutional review committees at each field center and individuals in the present analysis had available DNA and gave informed consent including consent to use of genetic information for the study of cardiovascular disease. COPDGene: All COPDGene participants provided written informed consent, and the study was approved by the Institutional Review Boards of the participating clinical centers. FHS: The Framingham Heart Study was approved by the Institutional Review Board of the Boston University Medical Center. All study participants provided written informed consent. HCHS/SOL: This study was approved by the institutional review boards (IRBs) at each field center, where all participants gave written informed consent, and by the Non-Biomedical IRB at the University of North Carolina at Chapel Hill, to the HCHS/SOL Data Coordinating Center. All IRBs approving the study are: Non-Biomedical IRB at the University of North Carolina at Chapel Hill. Chapel Hill, NC; Einstein IRB at the Albert Einstein College of Medicine of Yeshiva University. Bronx, NY; IRB at Office for the Protection of Research Subjects (OPRS), University of Illinois at Chicago. Chicago, IL; Human Subject Research Office, University of Miami. Miami, FL; Institutional Review Board of San Diego State University. San Diego, CA. JHS: The Institutional Review Boards at Jackson State University, Tougaloo College, and the University of Mississippi Medical Center approved the study, and all participants provided written informed consent. MESA: All MESA participants provided written informed consent, and the study was approved by the Institutional Review Boards at The Lundquist Institute (formerly Los Angeles BioMedical Research Institute) at Harbor-UCLA Medical Center, University of Washington, Wake Forest School of Medicine, Northwestern University, University of Minnesota, Columbia University, and Johns Hopkins University. WHI: All WHI participants provided informed consent and the study was approved by the Institutional Review Board (IRB) of the Fred Hutchinson Cancer Research Center. The Human Phenotype Project's data used in this work was approved by the Weizmann Institute's IRB for the 10K study, protocol 578-1. The MyCode Study was approved by the Geisinger Institutional Review Board and all participants provided informed consent. The current analysis consisted of secondary analysis of existing de-identified data and was deemed to be not human subjects research as defined in 45 CFR 46.102(f).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
